Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products
National Institutes of Health (NIH)
Total funding amount: Up to $4,466,000 per fiscal year
Maximum budget per project: $400,000 per year
Project duration: Up to two years
To provide early-stage translational support for the development of therapeutic agents for HLBS diseases.
Researchers and organizations involved in HLBS disease research and development.
Funding source: National Heart, Lung, and Blood Institute (NHLBI)
Funding type: Grant
Recurring grant opportunity with multiple application cycles.
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Indian/Native American Tribal Governments (Federally Recognized)
Indian/Native American Tribal Governments (Other than Federally Recognized)
Must have an eRA Commons account for Program Directors/Principal Investigators.
Organizations must be based in the United States.
At least one Accelerator Partner is required.
Development of therapeutic agents for HLBS diseases.
Identification of a lead compound series for preclinical testing.
Applicants must demonstrate expertise in therapeutic development.
Minimum cash match of 25% of the federal direct costs.
Application due date: June 17, 2027
Must comply with NIH Grants Policy Statement.
Preliminary IP and regulatory strategies must be included.